Format
Sort by

Send to

Choose Destination

Links from Books

Items: 6

1.

Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.

Wild D, Wicki A, Mansi R, Béhé M, Keil B, Bernhardt P, Christofori G, Ell PJ, Mäcke HR.

J Nucl Med. 2010 Jul;51(7):1059-67. doi: 10.2967/jnumed.110.074914.

2.

Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.

Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, Egan JM.

Am J Physiol Endocrinol Metab. 2006 Mar;290(3):E550-9.

3.

Glucagon-like peptide 1(GLP-1) in biology and pathology.

Meier JJ, Nauck MA.

Diabetes Metab Res Rev. 2005 Mar-Apr;21(2):91-117. Review.

PMID:
15759282
4.

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.

Nielsen LL, Young AA, Parkes DG.

Regul Pept. 2004 Feb 15;117(2):77-88. Review.

PMID:
14700743
5.
6.

Glucagon-like peptide-1.

Doyle ME, Egan JM.

Recent Prog Horm Res. 2001;56:377-99. Review.

PMID:
11237222
Items per page

Supplemental Content

Support Center